Surface Oncology
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch SURF and buy or sell other stocks, ETFs, and their options commission-free!About SURF
Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114).
CEORobert W. Ross, MD
CEORobert W. Ross, MD
Employees—
Employees—
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2014
Founded2014
Employees—
Employees—
SURF Key Statistics
Market cap65.08M
Market cap65.08M
Price-Earnings ratio-0.70
Price-Earnings ratio-0.70
Dividend yield—
Dividend yield—
Average volume292.98K
Average volume292.98K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$1.43
52 Week high$1.43
52 Week low$0.555
52 Week low$0.555
Stock Snapshot
With a market cap of 65.08M, Surface Oncology(SURF) trades at $1.07. The stock has a price-to-earnings ratio of -0.70.
Surface Oncology(SURF) stock opened on 2025-12-08 at —. The price climbed to — and dipped to —.
Surface Oncology(SURF) shares are trading with a volume of 0, against a daily average of 292.98K.
During the past year, Surface Oncology(SURF) stock moved between $0.56 at its lowest and $1.43 at its peak.
During the past year, Surface Oncology(SURF) stock moved between $0.56 at its lowest and $1.43 at its peak.
People also own
Based on the portfolios of people who own SURF. This list is generated using Robinhood data, and it’s not a recommendation.